Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 275Carcinoma, Intraductal, Noninfiltrating 25Breast Carcinoma In Situ 21Neoplasm Metastasis 14Neoplasms 13Breast Neoplasms, Male 12Ovarian Neoplasms 10Inflammatory Breast Neoplasms 7Glioblastoma 6Endometrial Neoplasms 6Prostatic Neoplasms 5Central Nervous System Neoplasms 5Gliosarcoma 4Fallopian Tube Neoplasms 4Breast Cancer Female 4Brain Neoplasms 4Recurrence 3Obesity 3Hot Flashes 3Glioma 3Carcinoma, Ovarian Epithelial 3Carcinoma, Ductal, Breast 3Breast Diseases 3Astrocytoma 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Sleep Wake Disorders 2Sarcoma 2Pancreatic Neoplasms 2Oligodendroglioma 2

Interventions

Tamoxifen 1Medroxyprogesterone Acetate 1Letrozole 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced, Persistent, or Recurrent Endometrial Cancer × Tamoxifen × Clear all
NCT02228681 2024-09-19

Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer

GOG Foundation

Phase 2 Completed
74 enrolled 13 charts
Gynecologic

Advanced, Persistent, or Recurrent Endometrial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡